This is a proposal to renew and to expand an existing drug abuse treatment research Center that focuses on the human behavioral pharmacology of addiction treatment. The Center will emphasize two themes: The first is evaluation of the soon-to-be-FDA-approved opioid maintenance pharmacotherapy LAAM (1-alpha-acetyl-methadol), which has been under development for several decades. Research on this theme will provide important human laboratory data and controlled outpatient clinical trial data concerning how and when to use this newly-available treatment medication most effectively. The second theme is assessment of psychiatric comorbidity and of the relationship to treatment response of these individual differences in patient characteristics. Research on this theme will identify important individual-difference modulators of treatment response and will aid in the pursuit of strategies for optimal patient- treatment matching. The Center consists of four components. The Core component provides essential central shared resources to all components; these include psychiatric assessment, computer, statistical, subject recruiting, pharmacy, urinalysis, secretarial, and administrative support services. Psychiatric assessments will permit stratification of clinical trials according to presence/absence of antisocial personality disorder, so that potential differential response of this important subgroup may be examined. The Human Laboratory component will conduct rigorously controlled, double blind, dose-response studies of LAAM's effects and of procedures for optimizing induction onto LAAM treatment The BPRU Research Clinic component will conduct rigorously controlled outpatient clinical trials of LAAM's dose-response relation and of its treatment efficacy in comparison to other available treatment medications (methadone and buprenorphine). The SEBDTP Treatment Clinic component will conduct, in a community treatment clinic, randomized clinical trials of the structured non-pharmacological treatments that accompany methadone and LAAM pharmacotherapy. These studies will provide critical data to guide practitioners in the successful incorporation of LAAM into routine clinical treatment of opioid drug abuse and in the appropriate recognition and treatment of drug abusers with antisocial personality disorder. Effective LAAM treatment and effective behavioral treatment adjuncts should contribute to reduction of HIV infection and AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005273-07
Application #
2117532
Study Section
Special Emphasis Panel (SRCD (53))
Project Start
1988-09-30
Project End
1998-07-31
Budget Start
1994-09-01
Budget End
1995-07-31
Support Year
7
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Peirce, Jessica M; Kindbom, Kori A; Waesche, Matthew C et al. (2008) Posttraumatic stress disorder, gender, and problem profiles in substance dependent patients. Subst Use Misuse 43:596-611
Burke, Christopher K; Peirce, Jessica M; Kidorf, Michael S et al. (2008) Sleep problems reported by patients entering opioid agonist treatment. J Subst Abuse Treat 35:328-33
Wedam, Erich F; Bigelow, George E; Johnson, Rolley E et al. (2007) QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 167:2469-75
Sigmon, Stacey C (2007) Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement. Exp Clin Psychopharmacol 15:1-20
Carroll, C Patrick; Kidorf, Michael; Strain, Eric C et al. (2007) Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting. J Subst Abuse Treat 33:355-61
Sigmon, Stacey C; Moody, David E; Nuwayser, Elie S et al. (2006) An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 101:420-32
Lott, David C; Strain, Eric C; Brooner, Robert K et al. (2006) HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. J Subst Abuse Treat 31:187-94
Jones, Hendree E; Fitzgerald, Heather; Johnson, Rolley E (2005) Males and females differ in response to opioid agonist medications. Am J Addict 14:223-33
Lofwall, Michelle R; Brooner, Robert K; Bigelow, George E et al. (2005) Characteristics of older opioid maintenance patients. J Subst Abuse Treat 28:265-72
Disney, Elizabeth R; Kidorf, Michael; King, Van L et al. (2005) Prevalence and correlates of cocaine physical dependence subtypes using the DSM-IV in outpatients receiving opioid agonist medication. Drug Alcohol Depend 79:23-32

Showing the most recent 10 out of 44 publications